Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.4%) at 16,500 as of Friday, April 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,273 issues advancing vs. 1,704 declining with 143 unchanged.

The Drugs industry currently sits down 3.6% versus the S&P 500, which is down 0.5%. Top gainers within the industry include Mylan ( MYL), up 4.1%, and Merck ( MRK), up 0.6%. On the negative front, top decliners within the industry include Illumina ( ILMN), down 6.2%, Alexion Pharmaceuticals ( ALXN), down 5.4%, Valeant Pharmaceuticals International ( VRX), down 4.4%, Regeneron Pharmaceuticals ( REGN), down 2.7% and Gilead ( GILD), down 2.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Abbott Laboratories ( ABT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.51 (1.3%) to $39.16 on average volume. Thus far, 3.9 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 8.5 million shares. The stock has ranged in price between $38.83-$39.50 after having opened the day at $38.87 as compared to the previous trading day's close of $38.65.

Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $59.5 billion and is part of the health care sector. Shares are up 0.8% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Abbott Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Eli Lilly and Company ( LLY) is up $0.50 (0.8%) to $59.47 on light volume. Thus far, 2.0 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $59.15-$59.96 after having opened the day at $59.22 as compared to the previous trading day's close of $58.97.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and Company has a market cap of $66.2 billion and is part of the health care sector. Shares are up 15.6% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate Eli Lilly and Company a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.92 (0.9%) to $99.18 on average volume. Thus far, 4.4 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $98.39-$99.38 after having opened the day at $98.62 as compared to the previous trading day's close of $98.26.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $277.8 billion and is part of the health care sector. Shares are up 7.3% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Lam Research: Cramer's Top Takeaways

Lam Research: Cramer's Top Takeaways